Latest market price
6.38
-0.25-3.77%
OverviewShort InterestFilings
CAPRQT40Capricor Therapeutics, Inc.·NASDAQ
6.38-3.77%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-2.45Insider Own37.69%Shs Outstand57.91MPerf Week7.59%
Market Cap369.48MForward P/E—EPS next Y-1.46Insider Trans-0.22%Shs Float52.65MPerf Month-28.64%
Enterprise Value221.48MPEG—EPS next Q-0.13Short Float37.72%Perf Quarter51.90%
Income-130.00MP/S—EPS this Y—Short Ratio2.81Perf Half Y-79.36%
Sales0.00P/B1.50EPS next Y—ROA-35.10%Short Interest19.86MPerf YTD-77.89%
Book/sh4.25P/C1.55EPS next 5Y—ROE-56.60%52W High40.37 -84.20%Perf Year-7.80%
Cash/sh4.11P/FCF—EPS past 3/5Y—ROIC-40.08%52W Low2.96 115.54%Perf 3Y128.67%
Dividend Est.—EV/EBITDA0.19Sales past 3/5Y—Gross Margin0.00%Volatility8.50% 7.84%Perf 5Y67.02%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.62Perf 10Y-80.78%
Dividend Ex-Date—Quick Ratio7.35Sales Y/Y TTM-100.00%Profit Margin0.00%RSI (14)41.60Recom2.20
Dividend Gr. 3/5Y—Current Ratio7.35EPS Q/Q-22.81%SMA20-6.64%Beta0.68Target Price12.70
Payout0.00%Debt/Eq0.37Sales Q/Q—SMA50-20.81%Rel Volume0.54Prev Close6.63
Employees231LT Debt/Eq0.37EarningsNov 09SMA200-69.14%Avg Volume5.94MPrice6.38
IPO DateFeb 13, 2007Option/ShortYes / YesEPS/Sales Surpr.-18.87% —Net Debt/EBITDA-0.13Volume3,213,293Change-3.77%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-14-26UpgradeB. Riley SecuritiesNeutral → Buy$21
Sep-01-26UpgradePiper SandlerNeutral → Overweight$45 → $25
Aug-14-26UpgradeCantor FitzgeraldNeutral → Overweight
Jul-31-26DowngradeJones TradingBuy → Hold
Jul-30-26DowngradeHC Wainwright & Co.Buy → Neutral
Jul-30-26DowngradeCantor FitzgeraldOverweight → Neutral$3.50
Jul-30-26DowngradePiper SandlerOverweight → Neutral
Jul-28-26ReiteratedIndustrial Alliance Securities$48 → $7.00
Jul-27-26ReiteratedRoth CapitalBuy$38 → $7.00
May-15-26ReiteratedRoth CapitalBuy$43 → $38
Latest News· Times ET
Oct-21-26
Oct-21-2603:52PM
CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision NearsYahoo
Oct-13-26
Oct-13-2603:02PM
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy - SlideshowSeekingAlpha
Oct-07-26
Oct-07-2607:02PM
Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nearsmarketbeat.com
04:12PM
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy TranscriptSeekingAlpha
Oct-05-26
Oct-05-2609:00AM
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congressglobenewswire.com
Sep-30-26
Sep-30-2611:56AM
Inflation Breather Could Help Stocks Finish Q3 Strongschaeffersresearch.com
10:30AM
Which stocks are gapping on Wednesday?ChartMill
Sep-28-26
Sep-28-2610:58AM
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026businesswire.com
10:14AM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPRglobenewswire.com
05:47AM
CAPR Investor Lawsuit: Capricor Therapeutics Sued for Securities Fraud on behalf of Investors with Losses – Contact BFA Law by September 28 Court Deadlineglobenewswire.com
02:11AM
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Lawprnewswire.com
02:10AM
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRprnewswire.com
Sep-27-26
Sep-27-2610:23PM
CAPR INVESTOR DEADLINE: Rosen Law Firm Reminds Capricor Therapeutics, Inc. Investors of September 28 Lead Plaintiff Deadline in Securities Class Actionnewsfilecorp.com
10:00AM
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadlinenewsfilecorp.com
Sep-26-26
Sep-26-2610:22PM
CAPR DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPRnewsfilecorp.com
Company

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue002225—————
Cost of Goods Sold Incl. D&A2005036—————
Gross Profit-200-28-11—————
Selling, General and Administrative Excl. Other35231513—————
Research and Development99845036—————
Other Operating Expense-191-50-36—————
Operating Income-135-108-43-24—————
Interest Expense3300—————
Unusual Expense
—————————
Non-Operating Income (Expense)9622—————
Net Income Before Taxes-130-105-40-22—————
Income Taxes
0000—————
Consolidated Net Income-130-105-40-22—————
Net Income From Continuing Operations-130-105-40-22—————
Net Income-130-105-40-22—————
EPS (Recurring)-2.45-2.26-1.15-0.83—————
EPS (Basic, Before Extraordinaries)-2.45-2.26-1.15-0.83—————
EPS (Diluted)-2.45-2.26-1.15-0.83—————
EBITDA1,174-100-39-21—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio——21.955.28—————
Gross Margin——-127.27-44.00—————
Operating Margin——-195.45-96.00—————
Net Margin——-181.82-88.00—————
Shares Outstanding58463527—————
Market Capitalization3701,328483132—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$40.06$29.83$19.60$9.36$-0.87● Close Price0.00M0.84M1.68M2.52M3.35MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 25 '26Option Exercise3.1824,10076,63835,323Jun 29
Krasney KarenEVP, GENERAL COUNSELJun 25 '26Sale30.3824,100732,15830,547Jun 29
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 25 '26Sale30.3824,100732,15811,223Jun 29
Krasney KarenEVP, GENERAL COUNSELJun 25 '26Option Exercise3.1824,10076,63854,647Jun 29
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 24 '26Sale30.0040012,00011,223Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 24 '26Option Exercise3.184001,27211,623Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 24 '26Option Exercise3.184001,27230,947Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 24 '26Sale30.0040012,00030,547Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 22 '26Option Exercise3.185001,59031,047Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 22 '26Option Exercise3.185001,59011,723Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 18 '26Option Exercise1.393,0004,17011,223May 19
Litvack FrankDirectorMay 13 '26Option Exercise1.393,9375,472133,776May 14
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 01 '26Option Exercise3.1825,00079,50033,223May 04
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 01 '26Sale31.7025,000792,5408,223May 04
Krasney KarenEVP, GENERAL COUNSELMay 01 '26Option Exercise3.1825,00079,50055,547May 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.